Introduction to kidney dose-response for radionuclide therapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 3, 2004, Pages 357-358

  Sgouros, George ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOISOTOPE;

BEAM THERAPY; BLOOD TOXICITY; DOSE RESPONSE; DRUG SAFETY; EDITORIAL; HUMAN; KIDNEY FAILURE; MOLECULAR WEIGHT; NEPHROTOXICITY; PRIORITY JOURNAL; RADIATION DOSE; RADIOISOTOPE THERAPY;

DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; NEOPLASMS; RADIOISOTOPES; RADIOTHERAPY DOSAGE;

EID: 3142685294     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/1084978041425061     Document Type: Editorial

References (4)

1. de Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings. Semin Nucl Med 2002;32:133.
2. Giralt S, Bensinger W, Goodman M, et al. Ho-166-DOTMP plus melphalan followed by peripheral blood stem-cell transplantation in patients with multiple myeloma: Results of two phase I/II trials. Blood 2003; 102:2684.
3. Russeva MG, Adams GP. Radioimmunotherapy with engineered antibodies. Expert Opin Biol Ther 2004;4:217.
4. Cybulla M, Weiner SM, Otte A. End-stage renal disease after treatment with 90Y-DOTATOC. Eur J Nucl Med 2001;28:1552.